Patents Assigned to Quantum Genomics
  • Combination of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
    Patent number: 10959938
    Abstract: The present invention relates to a pharmaceutical composition comprising, in at least one pharmaceutically acceptable support or vehicle, a combination of (3S,3S?)4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second active ingredient selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type I antagonists. Said composition is particularly useful for the treatment of hypertension and related diseases and conditions.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 30, 2021
    Assignee: Quantum Genomics
    Inventors: Catherine Llorens-Cortes, Yannick Marc, Ji Gao-Desliens, Fabrice Balavoine, Lionel Segard
  • Crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) with L-lysine
    Patent number: 9487477
    Abstract: The present invention relates to a new crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 8, 2016
    Assignee: Quantum Genomics
    Inventors: Fabrice Balavoine, Jean-Marie Schneider, Gérard Coquerel, Nicolas Couvrat
  • Crystalline phase of (3S.3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) with L-lysine
    Patent number: 9278921
    Abstract: The present invention relates to a new crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: March 8, 2016
    Assignee: Quantum Genomics
    Inventors: Fabrice Balavoine, Jean-Marie Schneider, Gérard Coquerel, Nicolas Couvrat
  • CRYSTALLINE PHASE OF (3S.3S') 4,4'-DISULFANEDIYLBIS(3-AMINOBUTANE 1-SULFONIC ACID) WITH L-LYSINE
    Publication number: 20150284325
    Abstract: The present invention relates to a new crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.
    Type: Application
    Filed: October 22, 2013
    Publication date: October 8, 2015
    Applicant: Quantum Genomics
    Inventors: Fabrice Balavoine, Jean-Marie Schneider, Gérard Coquerel, Nicolas Couvrat